

AXIRON NET SALES, QUARTER TO 31 MARCH 2015

Acrux (ASX: ACR) today confirmed that Eli Lilly reported Axiron net sales of USD\$39.1 million in its financial results for the quarter ended 31 March 2015. Net sales reported by Lilly for the same quarter to 31 March 2014 were USD\$39.5 million.

Royalties payable for the quarter are expected to be favourable versus the previous corresponding quarter based on exchange rate movements in the AUD:USD.

Contact

Michael Kotsanis, Chief Executive Officer: 03 8379 0100

About Acrux

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- The Acrux technology, used in marketed products including Axiron®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposits drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.